Immune Escape Mechanisms of Renal Cell Carcinoma

European Urology, Supplements

Volumn 6, Issue 10, 2007, Pages 616-622

  Seliger, Barbara ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Immune escape; MHC; RCC; T cell dysfunction

Indexed keywords

HLA G ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

CANCER SURVIVAL; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; KIDNEY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 34247191287     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.03.009     Document Type: Review

References (50)

1. Alexandrescu D.T., and Dasanu C.A. Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother 7 (2006) 2481-2493
2. Yang J.C., and Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 24 (2006) 5576-5583
3. Aalamian M., Fuchs E., Gupta R., and Levey D.L. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes. Urol Oncol 24 (2006) 425-433
4. Berntsen A., Geertsen P.F., and Svane I.M. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 50 (2006) 34-43
5. Kubler H., and Vieweg J. Vaccines in renal cell carcinoma. Semin Oncol 33 (2006) 614-624
6. Parton M., Gore M., and Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 24 (2006) 5584-5592
7. Patard J.-J. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb?. Eur Urol 50 (2006) 11-13
8. Wierecky J., Muller M.R., Wirths S., et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66 (2006) 5910-5918
9. Wang R.F., Zeng G., Johnston S.F., Voo K., and Ying H. T cell-mediated immune responses in melanoma: implications for immunotherapy. Crit Rev Oncol Hematol 43 (2002) 1-11
10. Passalacqua R., Buti S., Tomasello G., Longarini R., Brighenti M., and Dalla Chiesa M. Immunotherapy options in metastatic renal cell cancer: where we are and where we are going. Expert Rev Anticancer Ther 6 (2006) 1459-1472
11. Vieweg J., and Jackson A. Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin Biol Ther 4 (2004) 1791-1801
12. + T cells and shared among tumors of different histology. Clin Cancer Res 12 (2006) 4949-4957
13. Gouttefangeas C., Stenzl A., Stevanovic S., and Rammensee H.G. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 56 (2007) 117-128
14. Seliger B., Hohne A., Knuth A., et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56 (1996) 1756-1760
15. Seliger B., Maeurer M.J., and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 21 (2000) 455-464
16. Bukur J., Malenica B., Huber C., and Seliger B. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and in association with impaired immune response. Hum Immunol 64 (2003) 1081-1092
17. Atkins D., Ferrone S., Schmahl G.E., Storkel S., and Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?. J Urol 171 (2004) 885-889
18. Diegmann J., Junker K., Loncarevic I.F., Michel S., Schimmel B., and von Eggeling F. Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 8 (2006) 933-938
19. Finke J., Ferrone S., Frey A., Mufson A., and Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 20 (1999) 158-160
20. Uzzo R.G., Rayman P., Kolenko V., et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 5 (1999) 1219-1229
21. Whiteside T.L., and Rabinovich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 46 (1998) 175-184
22. Cabrera T., Lopze-Nevot M.A., Gaforio J.J., Ruiz-Cabello F., and Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52 (2003) 1-9
23. Seliger B., Cabrera T., Garrido F., and Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12 (2002) 3-13
24. Seliger B., Ritz U., and Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118 (2006) 129-138
25. Romero J.M., Aptsiauri N., Vazquez F., et al. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens 68 (2006) 303-310
26. Maleno I., Lopze Nevot M.A., Seliger B., and Garrido F. Low frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 in clear renal cell carcinomas. Int J Cancer 109 (2004) 636-638
27. Seliger B., Atkins D., Bock M., et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 9 (2003) 1721-1727
28. Hodson I., bock M., Ritz U., Brenner W., Huber C., and Seliger B. Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma. Int J Oncol 23 (2003) 991-999
29. Seliger B., Bock M., Ritz U., and Huber C. High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors. Int J Oncol 20 (2002) 349-353
30. Seliger B., Hammers S., Hohne A., et al. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res 3 (1997) 573-578
31. Hodge J.W., Greiner J.W., Tsang K.Y., et al. Costimulatory molecules as adjuvants for immunotherapy. Front Biosci 11 (2006) 788-803
32. Abken H., Hombach A., Heuser C., Kronfeld K., and Seliger B. Tuning tumor-specific T-cell activation: a matter of costimulation?. Trends Immunol 23 (2002) 240-245
33. Jung D., Hilmes C., Knuth A., Jaeger E., Huber C., and Seliger B. Gene transfer of the co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 50 (1999) 242-249
34. Kronfeld K., Abken H., and Seliger B. B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy. Int J Cancer 117 (2005) 794-799
35. Rouas-Freiss N., Moreau P., Ferrone S., and Carosella E.D. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. Cancer Res 65 (2005) 10139-10144
36. Bukur J., Rebmann V., Grosse-Wilde H., et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63 (2003) 4107-4111
37. Ibrahim E.C., Guerra N., Lacombe M.J., et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61 (2001) 6838-6845
38. Gastman B.R., Johnson D.E., Whiteside T.L., and Rabinowich H. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood 95 (2000) 2015-2023
39. Martinez-Lorenzo M.J., Anel A., Alava M.A., et al. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 295 (2004) 315-329
40. Adam P.J., Terrett J.A., Steers G., et al. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 95 (2006) 298-306
41. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002) 793-800
42. Krambeck A.E., Thompson R.H., Dong H., et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103 (2006) 10391-10396
43. Zhang J., Chen Y., Li J., et al. Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand). J Nephrol 19 (2006) 429-438
44. Biswas K., Richmond A., Rayman P., et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res 66 (2006) 6816-6825
45. Thornton M.V., Kudo D., Rayman P., et al. Degradation of NF-κB in T cells by gangliosides expressed on renal cell carcinomas. J Immunol 172 (2004) 3480-3490
46. Falkensammer C., Johrer K., Gander H., et al. IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses. Cancer Immunol Immunother 55 (2006) 1228-1237
47. Bukowski R.M., Rayman P., Uzzo R., et al. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res 4 (1998) 2337-2347
48. + regulatory T cells: current controversies and future perspectives. Eur J Immunol 36 (2006) 2832-2836
49. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24 (2006) 1169-1177
50. Zea A.H., Rodriguez P.C., Atkins M.B., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65 (2005) 3044-3048